Sprycel News and Research

RSS
On June 28, 2006, the FDA granted accelerated approval of SPRYCEL for the treatment of adults in all three phases of CML (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy including Gleevec. The FDA also granted full approval of SPRYCEL for the treatment of adults with Ph+ ALL with resistance or intolerance to prior therapy. SPRYCEL is the first approved oral tyrosine kinase inhibitor that, at nanomolar concentrations, inhibits BCR-ABL, SRC family (SRC, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRß kinases. The active ingredient of SPRYCEL is dasatinib. Dasatinib reduces the activity of one or more proteins responsible for the uncontrolled growth of the leukemia cells of patients with CML or Ph+ ALL.
ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

CytRx commences Phase 2 clinical trial of bafetinib for high-risk B-cell chronic lymphocytic leukemia

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Positive results from Phase 2 clinical trial for STA-9090 in Stage IIIB and Stage IV patients with NSCLC

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Synta Pharmaceuticals reports net loss of $9.3 million for first-quarter 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

EpiCept invites stockholders to attend Annual Meeting

EpiCept invites stockholders to attend Annual Meeting

High OOP costs discouraging many cancer patients from filling prescriptions

High OOP costs discouraging many cancer patients from filling prescriptions

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Bristol-Myers Squibb to review key accomplishments at meeting with investment community

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Researchers discover key reason why form of leukemia progresses from chronic phase to blast crisis

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Synta Pharmaceuticals' STA-9090 inhibits WT1 protein in AML

Sermo announces a new report on evolving trends in CML

Sermo announces a new report on evolving trends in CML

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals presents preclinical results of STA-9090 at AACR-IASLC Joint Conference

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Synta Pharmaceuticals initiates STA-9090 Phase 2 clinical trial for GIST

Phase 2 clinical study of STA-9090 in NSCLC initiated

Phase 2 clinical study of STA-9090 in NSCLC initiated

JCTM established to advance new research toward clinical applications

JCTM established to advance new research toward clinical applications

Beneficiaries may need to pay coinsurance for orally delivered oncology drugs, says new report

Beneficiaries may need to pay coinsurance for orally delivered oncology drugs, says new report